In The Specification:

NE

On page 5, line 7, replace "palmoate" with --pamoate--.

In The Claims:

Cancel claim 8. Please add new claims 10-12. Please amend claims 1-7 and 9 of this application as indicated below. The following listing of claims replaces all prior versions and listings of claims in this application:

1. (currently amended) A method for ~~producing~~ making ~~peptide salts, which comprises reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger, with a mixture of an acid and a basic ion exchanger during the formation of a free basic peptide, and then separating the ion exchanger and then the free basic peptide, with an inorganic or organic acid , and then forming the desired acid addition salt of the peptide, and removing the diluent~~ a composition containing a peptide salt having a pharmaceutically acceptable anion comprising:

a1

contacting a first peptide salt with a diluent to form a diluent solution;

contacting the diluent solution containing the first peptide salt with a mixed bed ion exchanger, wherein the mixed bed ion exchanger has strongly acidic cations and strong anion exchangers;

separating the mixed bed ion exchanger from the diluent solution;

contacting the diluent solution with an acid having a pharmaceutically acceptable anion, thereby forming an acid addition salt of the peptide having the pharmaceutically acceptable anion;

adding an adjuvant to the diluent solution; and

separating the diluent from the diluent solution.

2. (currently amended) The method of claim 1, wherein ~~said basic satarting peptide is a salt of~~ the first peptide salt is a salt of an LHRH antagonist selected from the group of Cetrorelix, Teverelix, Abarelix, Ganirelix, Azaline B, Antide, A-75998, Detirelix, Ramorelix, and RS-68439.

3. (currently amended) The method of claim 1, wherein said acid is ~~embonuc~~ embonic acid, stearic acid, or salicylic acid.

4. (currently amended) The method of claim 1, wherein ~~said basic starting peptide is~~ the first peptide salt is Cetrorelix acetate, and said acid is embonic acid, and the peptide:acid molar ratio is 2:1.

5. (currently amended) The method of claim 1, wherein said ~~diluent is removed by freeze dying~~ acid addition salt of the peptide is separated from the diluent by freeze drying.

a'

6. (currently amended) A ~~peptide salt when made by the process~~ composition comprising a peptide salt having a pharmaceutically acceptable anion made by the method of claim 1.

7. (currently amended) A pharmaceutical composition ~~which comprises~~ comprising ~~the~~ a peptide salt composition of claim 6, ~~together with~~ and at least one pharmaceutical adjuvant ~~, or~~ in a carrier.

8. (cancelled)

9. (currently amended) A ~~process~~ method of ~~treating a mammal with the peptide salt of claim 6, which comprises parenterally administering to the mammal a drug containing said peptide salt as active ingredient~~ treatment for benign prostate hyperplasia, myoma, or

endometriosis comprising parenterally administering to a patient a composition comprising a peptide salt having a pharmaceutically acceptable anion made by the method of claim 1, wherein a plasma level of greater than 2 ng/mL of an LHRH antagonist is maintained for at least 150 hours after administration.

10. (New) A method of treatment for benign prostate hyperplasia comprising parenterally administering to a patient 60 mg of a composition comprising a peptide salt having a pharmaceutically acceptable anion made by the method of claim 1, wherein a plasma level of greater than 2 ng/mL of cetrorelix is maintained for at least 150 hours after administration.

11. (New) A method of treatment for myoma comprising parenterally administering to a patient 60 mg of a composition comprising a peptide salt having a pharmaceutically acceptable anion made by the method of claim 1, wherein a plasma level of greater than 2 ng/mL of cetrorelix is maintained for at least 150 hours after administration.

a1

12. (New) A method of treatment for endometriosis comprising parenterally administering to a patient 60 mg of a composition comprising a peptide salt having a pharmaceutically acceptable anion made by the method of claim 1, wherein a plasma level of greater than 2 ng/mL of cetrorelix is maintained for at least 150 hours after administration.